Heron Therapeutics(US:HRTX)2025-11-04 13:30Financial Performance - Q3 2025 net revenue reached $38.2 million, and year-to-date revenue totaled $114.3 million[9] - Gross profit for Q3 2025 was $26.299 million, with a year-to-date gross profit of $84.088 million[34] - The company reported a loss from operations of $4.093 million for Q3 2025 and $2.576 million year-to-date[34] - Adjusted EBITDA for Q3 2025 was $1.542 million, and year-to-date adjusted EBITDA was $9.530 million[36] Product Performance - ZYNRELEF net sales in Q3 2025 were $9.3 million, a 49% increase year-over-year[9, 30] - APONVIE net sales in Q3 2025 were $3 million, a 173% increase year-over-year[9, 29] - Oncology Care Franchise net sales for the three months ended September 30, 2025, were $25.9 million[24] - Demand units for ZYNRELEF grew 30% between Q3 2024 and Q3 2025[19] - Demand units for APONVIE grew 142% between Q3 2024 and Q3 2025[23] Key Developments - ZYNRELEF average daily units increased 28% year-over-year, reaching 1,127 in Q3 2025 compared to 882 in Q3 2024[19] - APONVIE average daily units increased 139% year-over-year, reaching 998 in Q3 2025 compared to 418 in Q3 2024[23]